This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.
Fleiss JL, Levin B, Paik MC . Statistical Methods for Rates and Proportions, 2nd edn. John Wiley & Sons: New York, 1981, 352.pp.
Eudra (EU Drug Regulatory Authority for clinical trials registration) CT number 2006-003709-15.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verhagen, M., Wondergem, M. & Visser, O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant 43, 665 (2009). https://doi.org/10.1038/bmt.2008.378
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.378
This article is cited by
-
Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines
Supportive Care in Cancer (2020)
-
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2018)
-
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients
Supportive Care in Cancer (2013)